AXIM Biotechnologies Inc. (OTCMKTS: AXIM) has announced the publication of an article in the Journal of Clinical Virology detailing the development of a rapid COVID-19 neutralizing...
Axim Biotechnologies Inc (OTCMKTS: AXIM) has announced that it has created a second-generation Rapid Antibody Neutralizing Test for COVID-19. The test is known as ImmunoPass. T...
Axim Biotechnology Inc. (OTCMKTS:AXIM) has announced that its manufacturing partner Empowered Diagnostics has filed an Emergency Use Authorization (EUA) application with US FDA for ImmunoPass™’s approval....
AXIM® Biotechnologies Inc. (OTCMKTS:AXIM) has announced the commencement of ImmunoPass clinical trials. ImmunoPass is the company’s rapid point-of-care test that semi-quantitatively measures COVID-19 neutralizing antibody levels....
AXIM® Biotechnologies Inc. (OTCMKTS:AXIM) has completed a study focusing on the performance of its NeuCovix™ rapid test measuring the neutralizing levels of anti-COVID-19 antibodies. NeuCovix™ accurately...
Axim Biotechnologies Inc. (OTCMKTS:AXIM), an investment company of Medical Marijuana Inc. (OTCMKTS:MJNA), has announced the expansion of its research division by establishing an ultra-modern laboratory in...
In the imminent 12-18 months, Axim Biotechnologies Inc (OTCMKTS:AXIM) intends to accomplish a number of clinical programs. The company intends to conclude the open-label Phase 2...
As per a report issued by New Frontier Data, permitted cannabis sales in California are estimated to reach $2.8 billion in 2017, with a compound yearly...
SECFilings.com published an article covering the ophthalmology segment and Axim Biotechnologies Inc (OTCMKTS:AXIM) cannabinoid-based therapies. International ophthalmology revenue is expected to grow at a compound annual...
In the last trading session, the stock price of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) gained 0.32% to close the day at $111.16. GW Pharmaceuticals is a...